KANJINTI subst sèche 440 mg c solv flac
7680672050027
CH-67205
L01FD01
07.16.1.
Reimbursement limitations:
KANJINTI.01
KANJINTI en association avec le pertuzumab (PERJETA) comme traitement adjuvant du cancer du sein
Les …
1 / 3
google
Details
- Product number
- 6720502
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- Praeparatio cryodesiccata: trastuzumabum 440 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, pro vitro. Solvens: alcohol benzylicus 220 mg, aqua ad iniectabile, solutio reconstituta corresp. trastuzumabum 21 mg/ml.
Articles (1)
Kanjinti 440 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
PRC
|
440.0 MG | Substance | Wirkstoff (Principe actif) |
|
SOLV
|
220.0 MG | Substance | HBESI |
|
PRC
|
- | Substance | HNIDK |
|
SOLV
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
|
SOLV
|
21.0 MGML | Substance | Wirkstoff (Principe actif) |
|
PRC
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 1469.00
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/02/2020
Authorization holder
Amgen Switzerland AG
6343 Risch
Authorization information
- Swissmedic authorization number
- 67205
- Drug name
- Kanjinti, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- PULPI
- ATC Code
- L01FD01
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 11/11/2019
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- KANJINTI subst sèche 440 mg c solv flac
- Description (DE)
- KANJINTI Trockensub 440 mg c Solv Durchstf
- Market launch
- 11/11/2019
- Narcotic (BTM)
- No